MedTrace Logo

Potential Value of Immunohistochemical Expression of SOX17 and E-Cadherin in Variable Endometrial Lesions

NCT06132230 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2023-11-15

No results posted yet for this study

Summary

Endometrial carcinoma (EC) is the 6th most commonly occurring cancer in women and the 15th most common cancer overall According to facts derived from Globocan for the year 2020.The overall incidence was 417,367 and 97,370 died due to it. There were more than 417,000 new cases of endometrial cancer in 2020 .EC incidence is predicted to continue to rise in the coming decades, in particular among low and middle-income countries.

SOX17 protein (SRY-box 17) is a member of the SRY-related HMG-box (SOX) family of transcription factors that controls the first step of gene expression and regulates cellular growth and differentiation in the endoderm, during hematopoiesis, and in the cardiovascular system E-Cadherin is a calcium-dependent cell adhesion protein (predicted molecular weight of 97 kDa) that plays a vital role in cell migration and proliferation. The E-cadherin epithelial cell adhesion protein is a tumor suppressor that has an important role in tumor metastasis The loss of expression of E-Cadherin during the epithelial mesenchymal transition (EMT) is often thought to promote metastasis by allowing the dissociation and invasion of cancer cells

The aim of this study is:

1. To evaluate accuracy of SOX17 expression in neoplastic and hyperplastic endometrial lesions.
2. To correlate SOX17 expression with some clinical and pathological parameters of endometrial carcinoma.
3. To evaluate E-Cadhrin expression and its relation to SOX17 in neoplastic and hyperplastic lesions

Conditions

  • Variable Endometrial Lesions

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Principal Investigators

  • Gehad Bahgat · Sohag faculty of Medicine

Eligibility

Min Age
25 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-31
Primary Completion
2025-10-31
Completion
2025-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06132230 on ClinicalTrials.gov